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 Prior studies from our laboratory suggest that the -163 C > A polymorphism of the 
Cytochrome P450 (CYP1A2) gene influences the ergogenic effect of caffeine.  Although this 
polymorphism has been known to influence the inducibility of hepatic CYP1A2 and the rate of 
caffeine metabolism, levels of caffeine and/or metabolites have never been reported in these 
aforementioned studies (1, 12, 16).  Thus, a mechanistic link between the polymorphism and the 
ergogenic effect of caffeine is lacking. The purpose of this study was to determine if the CYP1A2 
polymorphism affected caffeine metabolism between the genotypes (AA homozygotes and C 
allele carriers). Twenty male subjects were recruited for this study. Subjects participated in two 
3km cycling time trials with placebo (all-purpose flour) and caffeine (6mg/kg body weight 
anhydrous caffeine) supplementation. “Slow metabolizers” were characterized as possessing a 
“C” allele on the first intron of that gene (grouped AC heterozygotes, and CC homozygotes), and 
“fast metabolizers” were those who were homozygous for the A allele. C allele carriers had 
significantly higher serum caffeine after one hour (C allele carriers = 14.2 ± 1.8 ppm, AA 
homozygotes = 11.7 ± 1.7 ppm).  While there was a main effect for caffeine ingestion on time 
trial performance, there was no caffeine x genotype interaction (C allele carriers: Placebo = 297 ± 
20.8 sec, Caffeine = 292 ± 20 sec; AA homozygotes: Placebo = 318.3 ± 34.5 sec; Caffeine = 
307.9 ± 21.9 sec). Results from this study suggest that C allele carriers have higher serum 
caffeine after one hour than AA homozygotes, consistent with the assertion that C allele carriers 
metabolize caffeine slower.  These findings do not support a genetic influence on the ergogenic 
effect of caffeine in a 3km cycling trial.  







Caffeine and performance 
The ergogenic effects of caffeine have been extensively studied over the past four 
decades. Although many studies have observed that caffeine improves performance, the extent of 
this ergogenic benefit can vary with respect to type of exercise, individual responses, and dosage 
(3, 11, 16, 34). Improvement in performance has been seen in endurance, resistance and high 
intensity exercise (3, 11, 16, 18, 33, 34). Furthermore, caffeine doses between 3 and 9mg/kg of 
body weight have been effective (3, 33). Up to 31% improvements in endurance performance 
have been observed with dosages ranging between 3-6 mg/kg of body weight (BW) (4, 16, 34). 
Several theories exist to explain the ergogenic effect of caffeine including increased lipolysis, 
free-fatty acid mobilization, and muscular force (3, 5, 9, 10, 14).  
It is commonly believed that caffeine competes with adenosine, a compound of similar 
chemical structure, to bind with adenosine receptors. When adenosine binds, it induces relaxation 
of the vascular smooth muscle, leading to vasodilation, decreased neuronal firing and release of 
neurotransmitters (NTs) (13). This reduces vasoconstriction and the shunting of the blood from 
the splanchnic region to the muscles (13). However, when caffeine is bound to adenosine 
receptors, adenosine is not able to bind, thus not able to exert this effect. Caffeine metabolites 
also have an affinity for caffeine receptors (13). With training, adenosine receptor density 
increases, exponentially increasing the potential effect of caffeine (13).  
Anaerobic Exercise 
Several studies have examined the effect of caffeine supplementation on short-duration 





15, 17, 30). Glaister et. al observed a 1.4% improvement in performance of twelve sets of thirty-
meter sprints with caffeine supplementation at 5mg/kgBW (15).  Carr et. al found a dosage of 
6mg/kgBW elicited a 1.1-1.6% observed improvement in sprint time with caffeine 
supplementation (7). Furthermore, Schneiker et. al also observed an improvement in total work in 
four-second sprints, with a dosage of 6mg/kg of body weight (30). An increase in anaerobic 
power has also been observed with caffeine supplementation. Anselme et. al observed an increase 
in maximal anaerobic power (Wmax) during a series of maximal sprints with 250mg ingested 
caffeine (2).  Time to exhaustion has also been observed to increase with caffeine 
supplementation in the short-duration/high-intensity domain (11, 12, 16, 17, 19).  
Endurance Performance 
The ergogenic effect of caffeine on endurance performance has also been observed in 
many studies at dosages ranging between 3-6mg/kgBW (3, 9, 17, 18, 19, 22, 25). Improved 
endurance performance has been observed across different modalities, including running and 
cycling (the two most often investigated). Jackman et. al observed a 20% increase in maximal 
cycling time to fatigue with caffeine supplementation (23). Bridge et. al found a 1.2% increase in 
8km run time of with 3mg/kgBW caffeine dose (4). McNaughton also observed an increase in 
cycling distance with 6mg/kgBW caffeine supplementation during three separate one-hour time 
trials (25). The effect on endurance performance appears to be greatest at moderate dose, between 
3-6mg/kgBW, propagating an improvement ranging from 1.2% to 31% (3, 4, 11, 23, 25). 
Genetic Influence of Caffeine Metabolism 
Cytochrome P450 1A2 (CYP1A2) is a hepatic enzyme is  primarily responsible for 
caffeine metabolism. The CYP1A2 enzyme breaks down caffeine into three primary metabolites: 
paraxanthine, theophylline, and theobromine (15, 22, 24). These metabolites are thought to have 





inhibiting the action of adenosine, similar to the action of caffeine (13). In fact, these metabolites 
are thought to potentially have a higher affinity for the adenosine receptors than caffeine, 
potentially making the effect of caffeine’s metabolites more potent than the effect of caffeine 
itself (13, 14, 24). The three metabolites have unique characteristics for their proposed effect on 
performance (3). Paraxanthine, the most common metabolite of caffeine, stimulates lipolysis; 
theophylline stimulates smooth muscle relaxation leading to increased vasodilation; and 
theobromine increases vasodilation and urine volume (3).  
 A single-neucleotide (A/C) polymorphism in intron 1 of the CYP1A2 gene affects the 
rate of caffeine metabolism in the liver (14, 29). This polymorphism leads to higher inducibility 
of the enzyme in AA homozygotes over C allele carriers (29). Sasche et. al observed a significant 
difference across genotypes for plasma caffeine in a group of smokers, with A/A homozygotes 
having significantly higher metabolic activity. This study recognized the increased prevalence of 
the polymorphism and the varying affects it caused across genotypes, and in smokers and non-
smokers (29). Several studies have since examined this polymorphism and have proposed that 
A/A homozygotes are fast metabolizers of caffeine in contrast to C allele carriers (8).  
The CYP1A2 polymorphism and health outcomes 
This polymorphism and its effect on caffeine metabolism have been associated with 
caffeine’s influence on the risk of myocardial infarction, hypertension, and lower bone mineral 
density (8, 19, 26). In 1,805 subjects, both with and without prior acute myocardial infarction 
(MI), C allele carriers had an increased risk for non-fatal myocardial infarction with caffeine 
ingestion; a risk not evident in A/A homozygotes. Via multivariate analysis, odds ratios were 
determined to be 1.19 (A/C) and 1.55 (C/C) compared to 1.00 in A/A homozygotes  (8). Palatini 
et. al  observed an increased risk of hypertension for slow caffeine metabolizers (C allele carriers) 





homozygotes had a higher risk for lower bone mineral density (BMD) with high caffeine 
consumption in comparison to C allele carriers. This study assessed BMD by Dual-energy X-ray 
absorptiometry (DXA) of the proximal femur (20). Thus the possession of a C allele at intron 1 
increases risk for acute MI, decreases risk for lower BMD, and decreases inducibility of the 
CYP1A2 enzyme (8, 20, 21, 29). 
The CYP1A2 polymorphism’s effect on the ergogenic properties of caffeine 
Studies from our laboratory have observed differences in ergogenic effect of caffeine 
between the aforementioned genotypes. It has been hypothesized that the different genotypes’ 
metabolize caffeine at different rates, which leads to a variance in caffeine response. In a group of 
competitive cyclists, Womack et. al observed a more pronounced ergogenic effect in A/A 
homozygotes, with an increased 40k time trial performance of 3.8 minutes as compared to a 1.3 
minute improvement in C allele carriers (35). In contrast, Pataky et. al observed a larger increase 
in 3k time trial performance in C allele carriers compared to over A/A homozygotes in 38 
recreationally trained cyclists (27). Conflicting with both studies, Algrain et al observed no 
differences in a 15-minute cycling performance between genotypes in 20 “modestly fit” subjects 
(1). Thus, the effect of the CYP1A2 polymorphism on the ergogenic response to caffeine is 
unclear.  Furthermore, while the aforementioned differences across genotypes in prior studies 
were assumed to be due to differences in caffeine metabolism, it has never been directly 
measured in conjunction with a study on caffeine supplementation and exercise performance. 
Therefore, the purpose of this study is to determine the effect that the CYP1A2 polymorphism has 
on caffeine metabolism and the ergogenic effect of caffeine. We hypothesize that C allele carriers 
will have increased performance, increased caffeine concentrations and decreased caffeine 









Twenty healthy male participants will be recruited for this study. All subjects will 
provide written consent before participating. It is estimated that approximately 45% will be AA 
homozygotes and 55% will possess a C allele (25, 33).  Recruitment will take place through 
James Madison University’s campus and community organizations and within the Harrisonburg 
community. The Institutional Review Board at James Madison University approved this study.  
Data Collection 
Descriptive Measures 
 Prior to the performance trials, subjects will perform a VO2max test on a Velotron™ cycle 
ergometer to obtain descriptive data. Subjects will warm-up on a treadmill at 3.5 mph for five 
minutes. Beginning wattage varied between trained and untrained individuals, with trained 
individuals beginning at 150W and increasing by 25 W every minute, and untrained individuals 
beginning at 100W with identical increases every minute. After the test began the intensity was 
increased by 15 watts every minute until the subject was too fatigued to continue. Metabolic data 
was collected continuously using a MOXUS® Modular VO2 system. VO2max was determined 
using the highest mean 30-sec value.  
Supplementation 
In a crossover, double-blind fashion, the subjects will be provided with caffeine treatment 





Supplementation ingestion will take place in the laboratory one hour prior to the start of the 
performance trials.  
Familiarization Trial 
The subjects will undergo two 3km time trials on a Velotron™ cycle ergometer as 
familiarization trials prior to their first performance trial. Subjects will be instructed to cycle the 
distance as fast as possible for both trials, identical to the protocol for the performance trials with 
the exception of supplement (treatment) ingestion. 
Performance Trials  
Subjects will complete a total of four performance trials at least three days apart (two 
morning and two afternoon trials). Morning and afternoon trials will be completed between the 
hours of 6:00am-10:00am and between 4:00pm-8:00pm respectively with at least eight hours 
between individual subjects’ morning and afternoon trials. Morning and afternoon trials will be 
analyzed separately for multiple studies. A venous blood draw will be taken upon entry to the 
laboratory and another prior to their exercise trial (60 minutes after ingestion of treatment or 
placebo). Subjects will then perform a 3k-time trial on a Velotron cycle ergometer.  
 Trials will be repeated in a crossover design for treatment and time of day with trials 
separated by at least three days in a double-blind fashion.  
Blood Analysis 
Blood will be drawn from an antecubital vein into serum vacutainer tubes. Samples will 
be spun in a refrigerated centrifuge (AccuSpin™) at 1500rpm for 20 minutes. The serum will be 





Serum caffeine (CAF), paraxanthine (PX), theobromine (TB), and theophylline (TP) will 
be analyzed using Mass Spectrometry as described previously (26).  
DNA will be obtained from whole blood samples using commercially available kits (GE 
Healthcare). The Department of Nutritional Sciences University of Toronto will perform 
genotyping using restriction fragment length polymorphism-polymerase chain reaction as 
described previously (7).   
Statistical Analysis 
3 km time, plasma caffeine and its metabolites (PX, TB, TP), as well as the 
paraxanthine:caffeine ration will be compared between genotypes (AA homozygotes and C-allele 
carriers) in both trials using paired t-tests. T-tests will also be used for 3km performance 
(treatment, genotype) and caffeine metabolism (treatment, time, genotype). Post-hoc testing will 
be performed using independent and dependent t-tests with a Bonferonni correction.  A priori 
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 Prior studies from our laboratory suggest that the -163 C > A polymorphism of the 
Cytochrome P450 (CYP1A2) gene influences the ergogenic effect of caffeine.  Although this 
polymorphism has been known to influence the inducibility of hepatic CYP1A2 and the rate of 
caffeine metabolism, levels of caffeine and/or metabolites have never been reported in these 
aforementioned studies (1, 12, 16).  Thus, a mechanistic link between the polymorphism and the 
ergogenic effect of caffeine is lacking.  The purpose of the present study was to determine if the 
CYP1A2 polymorphism affected caffeine metabolism and subsequent performance between the 
genotypes (AA homozygotes and C allele carriers). Twenty male subjects were recruited for this 
study. Subjects participated in two 3km cycling time trials with placebo (all-purpose flour) and 
caffeine (6mg/kg body weight anhydrous caffeine) supplementation. “Slow metabolizers” were 
characterized as possessing a “C” allele (grouped AC heterozygotes, and CC homozygotes), and 
“fast metabolizers” were those who were homozygous for the A allele. C allele carriers had 
significantly higher serum caffeine after one hour (C allele carriers = 14.2 ± 1.8 ppm, AA 
homozygotes = 11.7 ± 1.7 ppm).  While there was a main effect for caffeine ingestion on time 
trial performance, there was no caffeine x genotype interaction (C allele carriers: Placebo = 297 ± 
20.8 sec, Caffeine = 292 ± 20 sec; AA homozygotes: Placebo = 318.3 ± 34.5 sec; Caffeine = 
307.9 ± 21.9 sec). Results from this study suggest that C allele carriers have higher serum 
caffeine after one hour than AA homozygotes, consistent with the assertion that C allele carriers 
exhibit slower caffeine metabolism.  These findings do not support a genetic influence on the 









 The effect of caffeine on exercise performance has been thoroughly documented in a 
variety of activities (2, 5, 8, 9). Caffeine’s ergogenic effect is proposed to be related to its affinity 
for adenosine receptors. When adenosine is not bound to its receptors, the parasympathetic effect 
of adenosine is impaired, causing an increase in sympathetic activity (7). Caffeine’s metabolites: 
paraxanthine (PX), theobromine (TB), and theophylline (TP) also have an affinity for adenosine 
receptors, and have been theorized to have a higher affinity for those receptors than caffeine (7). 
Cytochrome P450 (CYP1A2) is the enzyme responsible for caffeine metabolism in the liver and 
converts it to the three major metabolites listed above.  
A single-nucleotide polymorphism (CYP1A2 -163 C > A) significantly affects the 
inducibility of this enzyme such that caffeine metabolism is faster in AA homozygotes and slower 
in C allele carriers (11, 13). Previous studies from this laboratory have observed differences in 
performance between these genotypes. Womack et al observed that caffeine improved 40km 
cycling performance to a greater extent in AA homozygotes than C allele carriers (both A/C 
heterozygotes and CC homozygotes) in 35 trained male cyclists (16). Conversely, Pataky et al 
found that C allele carriers observed a greater ergogenic benefit than AA homozygotes in a 3km 
cycling time trial (12). Algrain et al did not observe any significant differences in the effect of 
caffeine on a 15-minute performance trial between the genotypes and there was no main effect of 
caffeine observed (1).  
Clearly, the prior findings on the effect of this polymorphism on the ergogenic effect of 
caffeine are equivocal.  Furthermore, none of these prior studies have reported the influence of 
the polymorphism on caffeine metabolism.  Thus a mechanistic link between the polymorphism 
and the ergogenic benefit of caffeine is lacking. The aims of this study were to determine if the 





performance in young, healthy, male subjects. We hypothesized that C allele carriers would 
perform better in the 3km time trial as previously noted from the Human Performance Lab (12) 
and that C allele carriers would have higher serum caffeine concentrations and lower serum 





















Subjects: Twenty male subjects between the ages of 18-45 were recruited from the James 
Madison University and greater Harrisonburg area. The study was approved by James Madison 
University and all subjects gave informed consent prior to starting the study. This study was 
conducted in a double-blind fashion. Subjects reported to James Madison University’s Human 
Performance Lab for all visits, including a graded cycling test to determine VO2max, and four 3km 
cycling time trials (two familiarization trials, and two experimental trials).  
VO2max: All subjects participated in a graded exercise test on a Velotron cycle ergometer. 
Metabolic data was collected on a Moxus Modular VO2 system. Starting wattage was 150W for 
trained subjects, and 100W for untrained subjects, 25W were added every minute until volitional 
exhaustion. Heart rate, RPE, W, and VO2 was recorded every minute and VO2max was considered 
the largest minute-average. Subjects had an average VO2max of 57.2 ml/kg/min.  
3km Time Trials: Familiarization trials consisted of a 5-minute warm-up walk at 3.5mph on a 
treadmill. After the warmup, subjects performed a 3km time trial in order to reduce possible 
learning effects during repeated performance trials. All cycling trials were performed on a 
Velotron cycle ergometer.  
 Performance trials were conducted between the hours of 6:00am and 10:00am where 
supplementation was provided in a double-blind randomized order for each subject. Subjects 
were at least 4 hours post-prandial and abstained from caffeine and alcohol for 12 and 24 hours 
respectively prior to each trial. Diet and physical activity logs were collected from each subject 
prior to each trial and subjects were instructed to replicate diet and exercise logs as closely as 
possible. Supplementation for subjects was either 6mg/kg body weight of anhydrous caffeine 
(CAF) or all-purpose flour (PLA) in two gel capsules. A baseline venous blood draw was 





after supplement ingestion. Subjects then performed a 3km cycling time trial. Subjects were given 
information about distance traveled, and distance remaining during the trials but were blinded to 
time. This study was also part of a larger study where subjects participated in afternoon 3km time 
trials on separate days.  
Genotyping: DNA was obtained from whole blood samples using commercially available 
extraction kits (illustra blood genomicPrep mini spin kit; GE Healthcare; Pittsburgh, PA). 
Subjects were genotyped as previously described and grouped as AA homozygotes or C allele 
carriers (3). Due to the similarities in metabolism in all C allele carriers, as previously discussed 
(4, 13), we remained consistent with prior research (1, 4, 16) and combined CC homozygotes and 
heterozygotes into one group.   
Caffeine/Metabolite Assays: Serum was collected from the blood samples by centrifuging 
samples (AccuSpinTM) at 2500rpm for 15 minutes. Serum was stored in a -80 degree C freezer 
until thawed and prepared for mass spectrometry analysis. Mass spectrometry analysis was 
performed in the Chemistry Department at James Madison University.  
Statistical Analysis: Repeated measures analysis of variance was calculated to determine 
differences between caffeine and placebo treatment for individuals. Pearson correlation 
coefficients were calculated between the caffeine metabolite concentrations, ratio, and 










 There were eight AA homozygotes (40%), eight AC heterozygotes (40%), and four CC 
homozygotes (20%). Average performance times per group and individual performances within 
both trials are shown in Figures 1 and 2.  Figure 1 shows mean differences between groups in 
3km time trial performance. There was a main effect (P < 0.05) for caffeine on time trial 
performance in that caffeine resulted in an average improvement in the time trial of 7.11 ± 13.91 
sec (2.2%). Figure 2 shows individual performances for 3km time trials with caffeine and placebo 
supplementation. Any points that fall below the line of identity in this figure show an 
improvement in performance. There were four and five AA homozygotes and C allele carriers 
that improved performance respectively. There was also a strong trend (P = 0.054) for caffeine to 
improve average power output during the time trial (Placebo = 246.35  ± 56.41W, Caffeine = 
258.05  ± 50.65W).  There was not a significant caffeine x genotype interaction, as the AA 
homozygotes (Placebo = 318.28 ± 34.81 sec, Caffeine = 307.92 ± 21.89 sec) and C allele 
carriers (Placebo = 296.98 ± 20.82 sec, Caffeine = 292.03 ± 20.01 sec) had similar responses to 
caffeine.  Similarly, Power output (W) during the 3km cycling time trials was not different (P > 
0.05) between groups [AA homozygotes (Placebo = 223.50 ± 58.26W, Caffeine = 235.00 ± 
40.36W); C allele carriers (Placebo = 261.58 ± 49.62W, Caffeine = 273.42 ± 50.98W)]. 
 Average serum caffeine, caffeine metabolites, the paraxanthine:caffeine ratio and the 
metabolite:caffeine ratio for both genetic groups one hour after supplementation are shown in 
Table 1.  C allele carriers (14.17 ± 1.82 ppm) had significantly (P < 0.05) higher serum caffeine 
than AA homozygotes (11.65 ± 1.79 ppm).  There were no differences (P > 0.05) in any of the 
metabolites, the paraxanthine:caffeine ratio, or the metabolite:caffeine ratio between groups. 







 In the present study, we observed a significantly higher serum caffeine concentration one 
hour after supplementation in the C allele carriers compared with the AA homozygotes. This 
could be due to decreased rates of caffeine metabolism in this population. However, it should also 
be realized that there were no differences in the concentrations of the metabolites of caffeine, or 
the metabolites:caffeine ratio in the blood. It is possible that, because samples were taken from 
the blood, that metabolites were bound to the A1 adenosine receptors and immeasurable through 
this technique. While the higher serum caffeine levels and/or faster metabolism could be 
hypothesized to influence the ergogenic effects of caffeine, we did not observe a caffeine x 
genotype interaction in this study. Skinner et al previously observed that matching the timing of 
exercise performance with peak post-ingestion levels of caffeine does not influence the ergogenic 
effect. Thus, in the current study, the polymorphism could have affected metabolism without 
influencing subsequent performance (15).  
 Unlike prior studies from this laboratory (12, 16), we did not observe a genetic influence 
on the ergogenic effect of caffeine. Womack et al observed that caffeine doubled the average 
40km time trial improvement in AA homozygotes versus C allele carriers (16). In contrast, 
Pataky et al observed a “likely” larger improvement with caffeine supplementation for the C 
allele carriers over the AA homozygotes in a 3km time trial using magnitude based inferences 
(12). In the current study, caffeine improved performance in AA homozygotes by an average of 
11 seconds, versus 4 seconds in C allele carriers. That we did not observe a significant difference 
between the genetic groups may speak to a lack of power in the present study as the sample size 
in the current study and in the Algrain et al study (N = 20) were less than those reported for the 
Womack et al and Pataky et al studies (N = 35 and N = 38 respectively). There were differences 
in statistical method between the two studies done previously in the Human Performance Lab at 





magnitude based inferences (12, 16). Both studies saw a genotype effect within their respective 
statistical methods, but when both sets of data were analyzed using traditional statistics, only 
Womack et al showed a genotype x caffeine interaction, making our results similar to the 
traditional statistics results of Pataky et al, with no genotype by caffeine interaction (12, 16). Our 
results also corroborate the findings of Algrain et al, who found no differences in performance 
between genotypes during a 15-minute cycling performance test (1). Supplementation varied 
between studies, as Algrain et al used caffeine gum and pill ingestion used in the current study 
(1). Furthermore, unlike the present study, Algrain et al did not observe a significant main effect 
for caffeine, while there was a performance effect with caffeine supplementation in the current 
study.  
 It is worthwhile to explore potential reasons for the equivocal findings from the studies 
on this topic.  In addition to the potential sample size issues, there exists the possibility that the 
genetic influence on caffeine supplementation is only evident in studies in which a large effect 
size from caffeine occurs. Womack et al observed a 4.9% improvement in AA homozygotes in 
the 40km time trial (~3.7minute improvement) and 1.8% improvement in C allele carriers 
(~1.3minute improvement), which appears to be larger than the effects noted by Pataky et al 
consisting of a possible improvement in performance of 2.0% ± 4.0% in A/C heterozygotes and 
1.0% ± 3.2% in AA homozygotes (12, 16). Algrain et al observed minimal improvements in 
power output between genotypes (AA homozygotes = 0.02%; C allele carriers = 0.03%) (1). In 
the current study, we observed a 2.2% improvement in 3km time trial. The shorter duration trials 
may contribute to these conflicting results, as Doherty and Smith (6) showed that longer duration 
trials had significantly larger effect sizes with caffeine supplementation. It is reasonable to expect 
that the genetic influence on the variance in the ergogenic benefit of caffeine will be more 
pronounced when there is a greater effect of caffeine. However, we cannot definitively make this 





Training status may have also influenced our findings and previous studies. Our subjects 
ranged from recreationally trained, active males, to trained cyclists. While Womack et al, studied 
competitively trained male cyclists, Pataky et al studied recreationally trained males and females. 
Algrain et al studied males and females of “modest fitness” (1, 12, 16). Skinner et al found that 
trained subjects had lower peak caffeine concentrations than untrained subjects at the same 
dosage, suggesting that caffeine is metabolized faster in trained subjects (14). Fifty percent of the 
AA homozygotes in the current study consisted of trained cyclists, whereas 58% of the C allele 
carriers were trained. Due to the similar distribution between groups, training status likely did not 
affect our findings.  
 Limitations of this study include small effect size and small sample size. Further research 
is necessary in order to determine the true impact of the CYP1A2 polymorphism and its effect on 
both caffeine metabolism and the ergogenic effects of caffeine. Future studies should employ 
both expanded sample sizes and protocols designed to maximize effect size in order to gain full 
perspective of the effects that the polymorphism may have on caffeine metabolism and cycling 
performance. Results of this study seem to corroborate the differences in metabolism between the 
two genetic groups (C allele carriers having slower caffeine metabolism over AA homozygotes) 
with larger caffeine concentrations in the former group. However, with no differences in 
metabolites or metabolite ratio between groups, rate of metabolism is impossible to report. 
Furthermore, no influence of the CYP1A2 -163 C>A polymorphism on the ergogenic effect of 










1. Algrain HA, Thomas RM, Carrillo AE, et al. The Effects of a Polymorphism in the 
Cytochrome P450 CYP1A2 Gene on Performance Enhancement with Caffeine in Recreational 
Cyclists. Journal of Caffeine Research. 
2. Collomp K, Ahmaidi S, Chatard J, Audran M, Prefaut C. Benefits of caffeine ingestion on 
sprint performance in trained and untrained swimmers. Eur J Appl Physiol Occup Physiol. 1992; 
64(4):377-80. 
3. Cornelis MC, A El-Sohemy, and H Campos. Genetic polymorphism of CYP1A2 increases risk 
of myocardial infarction. J Med Genet. 2004;41:758-762. 
4. Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of CYP1A2 increases the risk 
of myocardial infarction. J Med Genet. 2004; 41(10):758-62. 
5. Doherty M. The effects of caffeine on the maximal accumulated oxygen deficit and short-term 
running performance. Int J Sport Nutr. 1998; 8:95-104. 
6. Doherty M, Smith PM. Effects of caffeine ingestion on exercise testing: a meta-analysis. Int J 
Sport Nutr Exerc Metab. 2004; 14(6):626-46. 
7. Fredholm BB. Adenosine, Adenosine Receptors and the Actions of Caffeine*. Pharmacol 
Toxicol. 1995; 76(2):93-101. 
8. Ganio MS, Klau JF, Casa DJ, Armstrong LE, Maresh CM. Effect of caffeine on sport-specific 
endurance performance: a systematic review. J Strength Cond Res. 2009; 23(1):315-24. 
9. Graham TE. Caffeine and exercise. Sports medicine. 2001; 31(11):785-807. 
10. Hallström H, Melhus H, Glynn A, Lind L, Syvänen A, Michaëlsson K. Coffee consumption 
and CYP1A2 genotype in relation to bone mineral density of the proximal femur in elderly men 
and women: a cohort study. Nutr Metab (Lond). 2010; 7(1):12. 
11. Han X, Ou-Yang D, Lu P, et al. Plasma caffeine metabolite ratio (17X/137X) in vivo 
associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics and 
Genomics. 2001; 11(5):429-35. 
12. Pataky MA, Womack CJ, Sauders Michael J, et al. Caffeine and 3-km Cycling Performance: 
Effects of Mouth Rinsing, Genotype, and Time of Day. SJMSS. 2015. 
13. Sachse C, Brockmöller J, Bauer S, Roots I. Functional significance of a C→ A polymorphism 
in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 
1999; 47(4):445-9. 
14. Skinner TL, Jenkins DG, Leveritt MD, et al. Factors influencing serum caffeine 






15. Skinner TL, Jenkins DG, Taaffe DR, Leveritt MD, Coombes JS. Coinciding exercise with 
peak serum caffeine does not improve cycling performance. Journal of Science and Medicine in 
Sport. 2013; 16(1):54-9. 
16. Womack CJ, Saunders MJ, Bechtel MK, et al. The influence of a CYP1A2 polymorphism on 



























Figure 1. Mean differences between groups in 3km time trial 
Figure 2. Shows individual 3km performances with placebo supplementation (x-axis) and 




Table 1:  Comparison of caffeine, paraxanthine (PX), theophylline (TP), and theobromine (TB), paraxanthine:caffeine ratio, and 
metabolites:caffeine between both genetic groups.  
* Significantly greater than the AA homozygote group (p<0.05) 
 
Caffeine ppm PX ppm TP ppm TB ppm PX:CAF Met:CAF 
AA Homozygotes 
(n = 8) 11.65 ± 1.79 0.78 ± 0.48 0.24 ± 2.94 0.06 ± 0.19 0.067 ± 0.04 
 
0.030 ± 0.02 
C Allele Carriers  
(n = 12) 14.17 ± 1.82* 0.78 ± 0.81 0.28 ± 2.94 0.24± 0.26 0.074 ± 0.12 
 
0.038 ± 0.05 































































































James Madison University 
Department of Kinesiology 
Consent for Investigative Procedure 
 
I, ______________________, hereby agree on _____________ (date) to participate in the 
research project conducted by Christopher J. Womack, Ph.D., Nicholas D. Luden, Ph.D., James 
Boyett, and Gabe Giersch from James Madison University titled The Effect of Genetics, Training 
Status, and Time-of-day Consumption on the Ergogenic Properties of Caffeine. 
The purpose of this study is to determine whether or not genetics influences the effects of 
caffeine supplementation on performance. Additionally, this study aims to determine whether 
trained individuals benefit more from caffeine supplementation than untrained during cycling 
and muscular strength performance. The final purpose of this study is to determine whether 
the time of day affects whether caffeine is beneficial for cycling performance.  
Subject Responsibility 
I understand that I will undergo the following testing in the study: 
This study consists of seven separate exercise tests performed on both on a muscle strength 
device and a stationary bike (cardiovascular fitness test, two familiarization tests, and four 3km 
time trial tests). All testing will occur in Godwin Hall, room 209, on the campus of James 
Madison University. You will also be asked about lifestyle behaviors such as smoking and 
physical activity and complete dietary and physical activity records. The total time commitment 
is estimated to be less than 10 hours over the course of 4-6 weeks. 
Pre-testing 1 (60 min):  
After completing this consent form and the health history screening, if you meet the inclusion 
criteria for the study, researchers will measure your height and body weight. 
You will then be asked to perform a maximal cardiovascular fitness test to determine your peak 
oxygen consumption (VO2max). You will be asked to ride a stationary bike at an initial workload 
that is ‘fairly easy’. The workload will then be increased every two minutes until exhaustion is 
reached, determined by either: 1) your request to stop due to fatigue, or 2) inability to maintain 





an accurate measurement of VO2max. To access oxygen consumption, you will need to breathe 
through a mouthpiece/breathing apparatus which collects expired air throughout the test (10-
15 minutes). 
Familiarization Trials (n =2; 30 minutes each):  
On two occasions, you will be asked to perform peak skeletal muscle function testing and a 3-
km cycling practice trial on a stationary bike. You will warm-up with a 5 minute treadmill test at 
3.5 mph, followed by a strength test. This will consist of two warm-up repetitions followed by 
two maximal exertion isokinetic peak torque measurements at 30, 120, and 240 degrees/sec. 
One set consists of two sub-maximal repetitions immediately followed by two maximal 
repetitions, with sixty seconds of rest between two sets at the same velocity. Once all exertions 
are completed at a given velocity, 60 seconds of rest will be given before proceeding to the next 
velocity. After strength testing is complete, you will move to a stationary bicycle to complete 
the 3-km time trial. You will be encouraged to treat the time trial like a competition. 
Experimental Trials (n=4; 120 minutes each): 
You will report to the laboratory 60 minutes prior to exercise testing. You will rest in a seated 
position for 5 minutes, after which a blood sample will be obtained for measurement of 
caffeine/caffeine metabolite levels (one of the samples will also be used to extract DNA for 
genotyping). Immediately following the blood draw, you will ingest either placebo or caffeine 
capsules, after which you will wait for ~60 minutes in the laboratory until exercise testing. 
Immediately prior to exercise testing, a second blood sample will be obtained for the 
measurement of caffeine/caffeine metabolite levels. Following the blood draw, you will 
complete the peak muscle function test and 3-km time trial described above.  
Supplementation Protocol: 
No supplementation will be given during the familiarization trials. You will be randomly assigned 
a treatment order. Treatments will be: 1. Placebo capsule containing flour administered 1hr prior 
to exercise at 8:00am 2. Caffeine capsule containing 6 mg/kg bodyweight caffeine administered 
1hr prior to exercise at 8:00am 3. Placebo capsule containing flour administered 1hr prior to 
exercise at 6:00pm 4. Caffeine capsule containing 6 mg/kg bodyweight caffeine administered 
1hr prior to exercise at 6:00pm. 
 
Dietary and Exercise Controls: 
You will be asked to record food intake 24 hours prior to the first familiarization trial. You will 
then be given a copy of the dietary log and asked to replicate food intake for 24 hours prior for 





consumption for 24 hours prior to testing in all trials. Additionally, you will be asked to arrive at 
the laboratory in a fasted state (no food intake within the past 4 hours). Finally, you will be 
asked to refrain from heavy exercise for 48 hours prior to testing, as well as record any physical 
activity during the 48 hours prior to testing. You will be asked to maintain consistent physical 
activity habits before all trials. 
DNA Sampling: 
We will extract a sample of your DNA from one of your blood samples. DNA and blood samples 
will be stored in our laboratory freezer for at least 3 years to allow us to conduct follow-up 
studies in the event that new discoveries are made related to DNA and caffeine metabolism. 
Your sample will be coded so that nobody except the primary investigators can identify which 
sample is yours. The DNA testing will involve determining sequences of DNA for specific genes 
that are related to caffeine metabolism. We will not use this DNA for any other purpose.  The 
results of this genetic testing will only be available to the primary investigator and you. These 
results will not be made public and will be stored in a locked file cabinet. 
Risks/Benefits: 
Skeletal Muscle Function 
The risks of muscle function testing include soreness from exertion 24-48 hours post and 
potential lightheadedness or loss of consciousness if correct form is not utilized.  You will be 
instructed in correct form and breathing techniques prior to testing. 
Cardiovascular Exercise (3-km Time Trial and VO2max test) 
According to the American College of Sports Medicine’s Guidelines for Exercise Testing and 
Prescription, the risk associated with heavy exercise for individuals categorized as “low risk” is 
very minimal, and physician supervision is not necessary.  The conditions that the exercise 
sessions are to take place are likely safer than the typical exercise environments of the subjects. 
If you do not meet ACSM criteria for “low risk”, you will not be allowed to participate in the 
study. In the unlikely event of cardiac or other complications during exercise, an emergency 
plan is in place. This includes immediate access to a phone to call emergency personnel. In 
addition, at least one of the listed investigators will be present during the exercise sessions, and 
all are CPR certified.   
Blood Sampling 
The risks of blood sampling using venipuncture include possible mild bruising, and the risk of 
transfer of blood-borne pathogens, as well as possible risks of infection or skin irritation.  These 





followed according to OSHA protocols, including: investigators will wear latex gloves at all times 
during blood sampling and testing. A sharps container lined with a biohazard bag will be used 
for all sharp objects involved in the blood sampling; all other materials (i.e. gloves, gauze pads, 
etc.) used during the sampling will be put in a separate waste disposal unit lined with a 
biohazard bag. All investigators who will be involved in blood draws (and handling of blood) 
have been trained in these phlebotomy techniques, and completed JMU blood-borne pathogen 
training. The total amount of blood obtained during this study is approximately 24 ml. For 
reference, this amount is ~ 6% of a can of soda, or 5% of the amount given when donating 
blood in a single session (approximately 1 pint, or 473 ml).  
Caffeine Ingestion 
The risks and side effects associated with caffeine supplementation include: rapid heart rate, 
elevated blood pressure, headache, nausea, vomiting, restlessness, agitation, and anxiet 
Performance incentive: 
The top 5 trained performers (fastest finishing placebo time, use of caffeine would necessitate 
an unfair advantage to possible genetic responders) will be entered into a drawing to win $150. 
Trained individuals in the top 6-10 placebo time will be entered into a drawing to win $75. An 
identical incentive method will be used for the untrained subjects (1 $150 and 1 $75). 
Confidentiality  
The results of this research will be presented at conferences and published in exercise science 
journals.  The results of this project will be coded in such a way that your identity will not be 
attached to the final form of this study.  The researcher retains the right to use and publish 
non-identifiable data.  However, you can ask that your data be removed from the study at any 
point prior to presentation and publication.  While individual responses are confidential, 
aggregate data will be presented representing averages or generalizations about the responses 
as a whole.  All data will be stored in a secure location accessible only to the researcher.  Final 
aggregate results will be made available to you upon request. 
Participation & Withdrawal  
Your participation is entirely voluntary.  You are free to choose not to participate.  Should you 
choose to participate, you can withdraw at any time without consequences of any kind.  Your 
right to withdraw includes the right to request that your DNA and blood samples be discarded 
at any time.  You should be aware that the DNA sample is subject to court subpoena. To dispose 
of your samples, your samples will be rinsed down a chemical drain in our laboratory or will be 
disposed of in a biohazard container. Again, your sample will not be identifiable without the 






You may have questions or concerns during the time of your participation in this study, or after 
its completion.  If you have any questions about the study, contact Nicholas D. Luden, Ph.D. at 
ludennd@jmu.edu or by phone at 540-568-4068. 
 
Giving of Consent 
I have read this consent form and I understand what is being requested of me as a participant 
in this study.  I freely consent to participate.  I have been given satisfactory answers to my 
questions.  The investigator provided me with a copy of this form.  I certify that I am at least 18 
years of age. 
   
Name of Participant  (Printed)  Name of Researcher(s)  (Printed) 
   
Name of Participant  (Signed)  Name of Researcher(s)  (Signed) 
   
  Date    Date 
 
For questions about your rights as a research subject, you may contact the chair of JMU’s 












AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire 
Assess your health status by marking all true statements 
 
History 
You have had: 
   a heart attack 
   heart surgery 
   cardiac catheterization 
   coronary angioplasty (PTCA)        
    pacemaker/implantable cardiac 
   defibrillator/rhythm disturbance 
   heart valve disease 
   heart failure 
   heart transplantation 
   congenital heart disease 
 
Symptoms 
   You experience chest discomfort with exertion 
   You experience unreasonable breathlessness 
   You experience dizziness, fainting, or blackouts 
   You take heart medications 
 
Other Health Issues 
   You have diabetes 
   You have asthma or other lung disease 
   You have burning or cramping sensation in your lower legs when walking short distances 
   You have musculoskeletal problems that limit your physical activity 
   You have concerns about the safety of exercise 




Cardiovascular risk factors 
   You are a man older than 45 years     
 You smoke, or quit smoking within the previous 6 months 
   Your blood pressure is > 140/90 mmHg 
   You do not know your blood pressure 
   You take blood pressure medication 
   Your blood cholesterol level is > 200 mg/dl 
   You do not know your cholesterol level 
   You have a close blood relative who had a heart attack or 
heart surgery before age 55 (father or brother) or age 65 (mother or sister) 
If you marked any of these 
statements in this section, consult 
your physician or other appropriate 
health care provider before engaging 
in exercise.  You may need to use a 
facility with a medically qualified 
staff. 
If you marked two or more of the 
statements in this section, you should 
consult your physician or other 
appropriate health care provider 
before engaging in exercise.  You 
might benefit from using a facility 
with a professionally qualified 






   You are physically inactive (i.e. you get < 30 minutes of physical activity on at least 3 days of the week) 
   You are > 20 pounds overweight 
 






















You should be able to exercise safely 
without consulting your physician or 
other appropriate health care 
provider in a self-guided program or 
almost any facility that meets your 





Subject Prescreening Information & Caffeine Habits 
Age: years 
Height       Weight      
Typical Exercise Habits over the Past 3-6 Months: 
Average number of days of cycling per week     
Average number of hours of cycling per week    
Briefly describe your cycling habits over the past 3-6 months: 
Average number of days of resistance exercise/weight lifting per week _____________ 
Average number of hours of resistance exercise/weight lifting per week _____________ 
Briefly describe your resistance training habits over the past 3-6 months: 
Do you have a muscle or joint injury/condition that precludes the completion of the cycling or muscle 
function protocol? If yes, please explain. 
Are you allergic to wheat? 
Do you have gluten intolerance? 




















Physical Activity Records 
Subject #    Trial #    Date:   
Date Type of Exercise Performed 
Duration of Exercise 
(minutes) 
Intensity of Exercise 
(use scale below) 
    
 
    
 








7 Very, very light 
8 
9 Very light 
10 
11 Fairly light 
12 




17 Very hard 
18 





24 Hour Diet Record 
 
Subject number____________  Date______________Day of Week_____________ 
Adapted From:  Lee RD, Nieman DC. Nutritional Assessment. 2nd ed. United States of America:
Time Food and/or Drink Method of Preparation Quantity Consumed Brand Name 
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